Drugmaker Shire said on Tuesday it was seeking to buy Baxalta for $30 billion to forge the leading global specialist in rare diseases.» Read More
A bird flu vaccine doesn't work well enough to approve it for emergency use against the current outbreak, the U.S. Department of Agriculture said.
A major Texas health insurer is feeling "blue" from some steep losses and now wants sharply higher prices for Obamacare plans next year.
South Korea's Health Ministry confirmed five additional cases of Middle East Respiratory Syndrome (MERS) on Thursday, raising the total to 35.
The CDC said doctors and state health officials should be on the lookout for people infected with the H5N2 bird flu virus, NBC reports.
Teva Pharmaceutical is looking to buy more shares in Mylan, positioning itself for a possible legal challenge to the generics drugmaker.
The figures are in: HealthCare.gov has about 6.4 million paying customers who are at risk of losing subsidies in a pending Supreme Court case.
South Korea confirmed five more cases of Middle East Respiratory Syndrome (MERS), bringing to 30 the number of infected people. Two people have died.
Many of the proposed rate increases of 10 percent or more for Obamacare health insurance plans have been revealed.
Since 1990 this stock sector has risen 5.2 percent. It's outperformed the broader market 65 percent of the time from May to October.
As a stock market analyst, Janet Yellen makes a pretty good Federal Reserve chair.
RBC Capital Markets' Michael Yee said the selloff of Puma Biotech is in an overreaction and that the stock will represents an opportunity in the long run.
The "Halftime Report" traders give their trades for the second half.
Proposals to deal with a potential Supreme Court ruling could merely delay serious disruption to the insurance market.
Despite disappointing trial results on Friday, the CEO of Bristol-Myers remains optimistic.
Merck's executive vice president Dr. Roger Perlmutter, discusses research on immunotherapy for certain colon cancers, and the players in the fight against cancer.
Pfizer's share of the market for certain cancer drugs has increased from 10 to 20 percent, Chairman and CEO Ian Read tells CNBC.
Millions of people could suffer if the Supreme Court strikes down Obamacare subsidies, two doctors tell CNBC.
CNBC's Meg Tirrell, and Pascal Soriot, AstraZeneca executive director & CEO, discuss the promising results in using immunotherapy to treat all kinds of cancers.
The stock-moving news flow started early out of the American Society of Clinical Oncology meeting in Chicago.
The health-care sector is hot, and investors don't have to bet on the riskiest biotech stocks to profit.
Get the best of CNBC in your inbox